A source sits within reach of the sentence.
I link each source beside the thought it explains. Here they are together, with a little help finding your way around. You can read further without having to hunt through every page again.
Names
FDA’s semax assessment covers its identity, Russian nasal-drop registration and gaps in human safety information. PubChem describes selank’s chemical identity. A clinical review discusses selank’s limited evidence. These sources help explain the names without treating either peptide as proven safe.
FDA’s epitalon assessment separates it from epithalamin extract. That distinction keeps research on one from becoming a claim about the other. FDA’s BPC-157 assessment looks at naming problems, limited human studies and safety gaps. The exact substance matters in both cases.
FDA’s thymosin alpha-1 assessment discusses foreign authorisations, lack of U.S. approval and safety concerns. Its Italy example describes a particular use. I keep those details beside the country name so approved overseas doesn’t have to carry the whole explanation.
The preparation sources add the next part of the explanation.
Preparations
FDA’s cosmetic explanation sets out rules that differ from drug approval. Its bulk-substance safety page, current as of April 22, 2026, names injectable GHK-Cu and lists withdrawn nominations. The safety concerns remain. That page date doesn’t tell us when any individual entry moved.
FDA’s compounding explanation describes the process and makes clear that compounded drugs aren’t FDA-approved. The 503A ingredient framework explains conditions for starting ingredients. These pages are useful background; they can’t assess a reader’s particular preparation or medical needs.
FDA’s unapproved-drug discussion covers semaglutide salts and misleading research-use labels. The semaglutide prescribing information covers approved forms and warnings. The medical boards’ telemedicine policy explains assessment and licensure. It’s professional policy, with state law still relevant. Each source answers a different part of the question.
Sport needs a separate set of dated documents.
Dates
WADA’s 2026 Prohibited List is in force on October 27, 2026. Its 2026 explanatory notes discuss monitoring semaglutide and tirzepatide. The 2027 Prohibited List takes effect January 1, 2027; the 2027 Monitoring Program is separate. A watch list and a banned list do different jobs.
The NCAA’s 2026–27 list covers American college sport. USADA’s exemption explanation concerns permission for medical use under the relevant sport rules. Neither document can replace a conversation about someone’s care. The governing body matters as well as the date.
The about page explains how I approach the reading. The contact page points personal questions towards the right conversation. A link gives you somewhere to look further; it doesn’t turn an unanswered question into a settled fact.
The source stays close enough to read for yourself.